Author: digi

Real-Time Pharmacovigilance Through Social Media Monitoring in Phase 4 Trials

June 14, 2025

Real-Time Pharmacovigilance Through Social Media Monitoring in Phase 4 Trials Harnessing Social Media for Real-Time Safety Signal Detection in Phase 4 Clinical Trials Introduction Modern pharmacovigilance extends beyond hospitals, registries, and electronic health records. In today’s digital age, patients share experiences in real time through social media platforms, health forums, and online communities. For sponsors…

Phase 4 (Post-Marketing Surveillance)

Efficiency Gains Using Factorial Methods – Clinical Trial Design and Protocol Development

June 14, 2025

digi

Efficiency Gains Using Factorial Methods – Clinical Trial Design and Protocol Development “Improving Efficiency Through Factorial Techniques” Introduction Efficiency is a critical aspect in clinical studies and pharmaceutical industries. Efficiency gains using factorial methods are increasingly becoming popular, as they help in enhancing productivity and reducing costs in the long run. A factorial method is…

Clinical Trial Design and Protocol Development, Factorial Designs

Documentation Transfer Protocols During Clinical Trial Site Close-Out Visits

June 14, 2025

digi

Comprehensive Guide to Documentation Transfer Protocols During Site Close-Out Visits Clinical trial site close-out visits (COVs) mark the formal conclusion of trial operations at a site. One of the most crucial components of this visit is the transfer of essential documentation from the site to the sponsor, Contract Research Organization (CRO), or archival facility. Properly…

Site Close-Out Visits, Site Management and Monitoring

Sponsor Expectations from Site Staff During Site Initiation Visits (SIV)

June 14, 2025

digi

What Sponsors Expect from Site Staff During Site Initiation Visits (SIV) The Site Initiation Visit (SIV) is a foundational step in clinical trial start-up, bridging site preparation and trial activation. It allows sponsors and Clinical Research Associates (CRAs) to confirm site readiness, align expectations, and train the site team on study-specific procedures. A successful SIV…

Site Initiation Visits, Site Management and Monitoring

Key Functions Commonly Outsourced via Functional Service Providers (FSPs)

June 14, 2025

digi

Key Functions Commonly Outsourced via Functional Service Providers (FSPs) Key Functions Commonly Outsourced via Functional Service Providers (FSPs) Functional Service Provider (FSP) outsourcing has become a strategic approach in clinical research, enabling sponsors to delegate specific operational functions to experienced external partners while maintaining control over study design and oversight. FSP models are flexible, scalable,…

Contract Research Organizations (CROs), Functional Service Providers (FSPs)

Documenting the Consent Process per GCP in Clinical Trials

June 14, 2025

digi

Documenting the Consent Process per GCP in Clinical Trials How to Document the Informed Consent Process According to GCP Guidelines Proper documentation of the informed consent process is critical for ensuring ethical compliance, patient safety, and regulatory audit readiness in clinical trials. Good Clinical Practice (GCP) guidelines, including ICH-GCP E6(R2), outline the specific documentation standards…

Informed Consent and Ethics Committees, Informed Consent Process

Planning for Drug-Device Combination Studies in Early Phase Trials

June 14, 2025

digi

Planning for Drug-Device Combination Studies in Early Phase Trials Designing Effective Phase 1 Trials for Drug-Device Combination Products Introduction With the rise of biologics, injectables, inhalers, wearable delivery systems, and on-body injectors, drug-device combination products are reshaping how therapies are administered. In early-phase trials, particularly Phase 1, these combinations pose unique challenges. Both the drug…

Phase 1 (Safety and Dosage)

Designing a Comprehensive Patient Retention Plan for Clinical Trials

June 14, 2025

digi

Designing a Comprehensive Patient Retention Plan for Clinical Trials Designing a Comprehensive Patient Retention Plan for Clinical Trials Patient retention is critical to the success of any clinical trial. While much attention is given to recruitment, the value of keeping participants engaged throughout the study cannot be overstated. Poor retention compromises statistical power, data completeness,…

Patient Recruitment and Retention, Retention Strategies

2×2 Factorial Designs in Clinical Research – Clinical Trial Design and Protocol Development

June 14, 2025

digi

2×2 Factorial Designs in Clinical Research – Clinical Trial Design and Protocol Development “Utilizing 2×2 Factorial Designs in Clinical Studies” Understanding 2×2 Factorial Designs in Clinical Research Clinical research is a field that relies heavily on statistical models and experimental design to generate reliable and informed results. One of the most commonly used experimental designs…

Clinical Trial Design and Protocol Development, Factorial Designs

Vendor Oversight and Performance Metrics in Global Phase 3 Programs: Managing Partners for Trial Success

June 14, 2025

digi

Vendor Oversight and Performance Metrics in Global Phase 3 Programs: Managing Partners for Trial Success How to Effectively Oversee Vendors and Track Performance in Global Phase 3 Trials Why Vendor Oversight Is Essential in Phase 3 Global Phase 3 trials involve extensive outsourcing—spanning CROs, central labs, imaging vendors, IRT systems, ePRO providers, and data management…

Phase 3 (Confirmation and Monitoring)